Other equities analysts have also recently issued research reports about the stock. Mizuho restated a buy rating and issued a $19.00 price objective (up previously from $18.00) on shares of Endo International PLC in a research note on Thursday, May 25th. Deutsche Bank AG dropped their target price on shares of Endo International PLC from $18.00 to $15.00 and set a buy rating for the company in a research report on Friday, July 7th. Morgan Stanley dropped their target price on shares of Endo International PLC from $12.00 to $8.00 and set an equal weight rating for the company in a research report on Thursday, August 10th. Royal Bank Of Canada set a $15.00 target price on shares of Endo International PLC and gave the stock a hold rating in a research report on Monday, June 12th. Finally, Stifel Nicolaus cut shares of Endo International PLC from a buy rating to a hold rating and dropped their target price for the stock from $22.00 to $15.00 in a research report on Friday, June 9th. Three analysts have rated the stock with a sell rating, sixteen have given a hold rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average target price of $14.33.
Shares of Endo International PLC (ENDP) opened at 8.60 on Friday. Endo International PLC has a 52-week low of $7.41 and a 52-week high of $23.98. The stock has a 50 day moving average of $8.88 and a 200 day moving average of $10.89. The company’s market cap is $1.92 billion.
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last released its earnings results on Tuesday, August 8th. The company reported $0.93 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.19. The firm had revenue of $875.73 million during the quarter, compared to analysts’ expectations of $832.66 million. Endo International PLC had a negative net margin of 126.93% and a positive return on equity of 37.58%. The business’s quarterly revenue was down 4.9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.86 EPS. On average, equities analysts anticipate that Endo International PLC will post $3.52 earnings per share for the current fiscal year.
WARNING: This article was published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://stocknewstimes.com/2017/09/18/endo-international-plc-endp-given-hold-rating-at-piper-jaffray-companies.html.
In related news, CEO Paul Campanelli bought 6,500 shares of the company’s stock in a transaction on Monday, August 14th. The shares were purchased at an average cost of $7.71 per share, for a total transaction of $50,115.00. Following the acquisition, the chief executive officer now owns 213,620 shares of the company’s stock, valued at approximately $1,647,010.20. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, COO Terrance J. Coughlin bought 20,000 shares of the company’s stock in a transaction on Thursday, August 10th. The shares were bought at an average price of $7.70 per share, for a total transaction of $154,000.00. Following the completion of the acquisition, the chief operating officer now directly owns 181,369 shares in the company, valued at approximately $1,396,541.30. The disclosure for this purchase can be found here. Insiders have acquired a total of 36,000 shares of company stock worth $279,460 over the last 90 days. Corporate insiders own 0.50% of the company’s stock.
A number of hedge funds have recently made changes to their positions in ENDP. Nationwide Fund Advisors raised its holdings in Endo International PLC by 400.0% during the 1st quarter. Nationwide Fund Advisors now owns 343,874 shares of the company’s stock worth $3,838,000 after buying an additional 275,101 shares during the period. Russell Investments Group Ltd. raised its holdings in Endo International PLC by 13.8% during the 1st quarter. Russell Investments Group Ltd. now owns 269,453 shares of the company’s stock worth $3,008,000 after buying an additional 32,760 shares during the period. Capital Fund Management S.A. acquired a new stake in Endo International PLC during the 1st quarter worth approximately $260,000. Bank of New York Mellon Corp raised its holdings in Endo International PLC by 38.7% during the 1st quarter. Bank of New York Mellon Corp now owns 2,271,111 shares of the company’s stock worth $25,345,000 after buying an additional 633,904 shares during the period. Finally, Comerica Bank raised its holdings in Endo International PLC by 233.7% during the 1st quarter. Comerica Bank now owns 153,881 shares of the company’s stock worth $1,736,000 after buying an additional 107,761 shares during the period. Hedge funds and other institutional investors own 90.71% of the company’s stock.
Endo International PLC Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.